Slim chance participants in phase 1 cancer trials will benefit
Only a tiny proportion of therapies are ultimately approved, researchers say
The chance that a therapy used on a patient in a phase 1 cancer trial will be later approved by the US Food and Drug Administration is almost as slim as one in a 100, a review suggests.
Only 1.2% of participants — in a total of 1000 phase 1 cancer drug trials — received a treatment that was later FDA-approved for the indication and dose they received.
Given published estimates of serious adverse event rates of 10%-19%, this represents low therapeutic value for